{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:11:32Z","timestamp":1789056692517,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,20]]},"DOI":"10.7759\/cureus.74117","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T05:07:02Z","timestamp":1732165622000},"source":"Crossref","is-referenced-by-count":3,"title":["Successful Control of Myasthenic Crisis After the Introduction of Ravulizumab in Myasthenia Gravis: A Case Report"],"prefix":"10.7759","author":[{"given":"Takafumi","family":"Uchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8206.1","article-title":"Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms","volume":"5","author":"Phillips WD","year":"2016","unstructured":"Phillips WD, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Res. 2016, 5:10.12688\/f1000research.8206.1","journal-title":"F1000Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli MN","year":"2009","unstructured":"Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009, 8:475-90. 10.1016\/S1474-4422(09)70063-8","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/cen3.12739","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"14","author":"Murai H","year":"2023","unstructured":"Murai H, Utsugisawa K, Motomura M, Imai T, Uzawa A, Suzuki S. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome. Clin Exp Neuroimmunol. 2023, 14:19-27. 10.1111\/cen3.12739","journal-title":"Clin Exp Neuroimmunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25397","article-title":"Early fast-acting treatment strategy against generalized myasthenia gravis","volume":"55","author":"Utsugisawa K","year":"2017","unstructured":"Utsugisawa K, Nagane Y, Akaishi T, et al.. Early fast-acting treatment strategy against generalized myasthenia gravis. Muscle Nerve. 2017, 55:794-801. 10.1002\/mus.25397","journal-title":"Muscle Nerve"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe GI","year":"2016","unstructured":"Wolfe GI, Kaminski HJ, Aban IB, et al.. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016, 375:511-22. 10.1056\/NEJMoa1602489","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2017.06.009","article-title":"Myasthenia gravis and crisis: evaluation and management in the emergency department","volume":"53","author":"Roper J","year":"2017","unstructured":"Roper J, Fleming ME, Long B, Koyfman A. Myasthenia gravis and crisis: evaluation and management in the emergency department. J Emerg Med. 2017, 53:843-53. 10.1016\/j.jemermed.2017.06.009","journal-title":"J Emerg Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard JF Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, et al.. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017, 16:976-86. 10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu T","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, et al.. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022, 1:EVIDoa2100066. 10.1056\/EVIDoa2100066","journal-title":"NEJM Evid"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard JF Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, et al.. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021, 20:526-36. 10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"55","author":"Jaretzki A 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards. Neurology. 2000, 55:16-23. 10.1016\/s0003-4975(00)01595-2","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6909a1","article-title":"Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020","volume":"69","author":"Mbaeyi SA","year":"2020","unstructured":"Mbaeyi SA, Bozio CH, Duffy J, Rubin LG, Hariri S, Stephens DS, MacNeil JR. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020, 69:1-41. 10.15585\/mmwr.rr6909a1","journal-title":"MMWR Recomm Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16711","article-title":"Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies","volume":"191","author":"Peffault de Latour R","year":"2020","unstructured":"Peffault de Latour R, Brodsky RA, Ortiz S, et al.. Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. Br J Haematol. 2020, 191:476-85. 10.1111\/bjh.16711","journal-title":"Br J Haematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122421","article-title":"Discordance between free C5 and CH50 complement assays in measuring complement C5 inhibition in patients with aHUS treated with ravulizumab","volume":"134","author":"Cataland S","year":"2019","unstructured":"Cataland S, Ariceta G, Chen P, et al.. Discordance between free C5 and CH50 complement assays in measuring complement C5 inhibition in patients with aHUS treated with ravulizumab. Blood. 2019, 134:1099. 10.1182\/blood-2019-122421","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237497","article-title":"Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"15","author":"Peipert JD","year":"2020","unstructured":"Peipert JD, Kulasekararaj AG, Gaya A, et al.. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS One. 2020, 15:e0237497. 10.1371\/journal.pone.0237497","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura J","year":"2014","unstructured":"Nishimura J, Yamamoto M, Hayashi S, et al.. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014, 370:632-9. 10.1056\/NEJMoa1311084","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11617-1","article-title":"Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis","volume":"270","author":"Vu T","year":"2023","unstructured":"Vu T, Ortiz S, Katsuno M, et al.. Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. J Neurol. 2023, 270:3129-37. 10.1007\/s00415-023-11617-1","journal-title":"J Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/9780470720721.ch12","article-title":"Mechanisms of acetylcholine receptor loss from the neuromuscular junction","volume":"90","author":"Engel AG","year":"1982","unstructured":"Engel AG, Fumagalli G. Mechanisms of acetylcholine receptor loss from the neuromuscular junction. Ciba Found Symp. 1982, 90:197-224. 10.1002\/9780470720721.ch12","journal-title":"Ciba Found Symp"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1831519","article-title":"A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome","volume":"23","author":"Wang Y","year":"2020","unstructured":"Wang Y, Johnston K, Popoff E, Myren KJ, Cheung A, Faria C, Tomazos I. A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome. J Med Econ. 2020, 23:1503-15. 10.1080\/13696998.2020.1831519","journal-title":"J Med Econ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-022-01556-5","article-title":"Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands","volume":"24","author":"Quist SW","year":"2023","unstructured":"Quist SW, Postma AJ, Myr\u00e9n KJ, de Jong LA, Postma MJ. Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands. Eur J Health Econ. 2023, 24:1455-72. 10.1007\/s10198-022-01556-5","journal-title":"Eur J Health Econ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06900-y","article-title":"Starting eculizumab as rescue therapy in refractory myasthenic crisis","volume":"44","author":"Vinciguerra C","year":"2023","unstructured":"Vinciguerra C, Bevilacqua L, Toriello A, Iovino A, Piscosquito G, Calicchio G, Barone P. Starting eculizumab as rescue therapy in refractory myasthenic crisis. Neurol Sci. 2023, 44:3707-9. 10.1007\/s10072-023-06900-y","journal-title":"Neurol Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11222-8","article-title":"Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report","volume":"269","author":"Strano CM","year":"2022","unstructured":"Strano CM, Sorrenti B, Bosco L, Falzone YM, Fazio R, Filippi M. Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report. J Neurol. 2022, 269:6152-4. 10.1007\/s00415-022-11222-8","journal-title":"J Neurol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27326","article-title":"The use of eculizumab in ventilator-dependent myasthenia gravis patients","volume":"64","author":"Usman U","year":"2021","unstructured":"Usman U, Chrisman C, Houston D, Haws CC, Wang A, Muley S. The use of eculizumab in ventilator-dependent myasthenia gravis patients. Muscle Nerve. 2021, 64:212-5. 10.1002\/mus.27326","journal-title":"Muscle Nerve"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10428-6","article-title":"Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19","volume":"268","author":"Hofstadt-van Oy U","year":"2021","unstructured":"Hofstadt-van Oy U, Stankovic S, Kelbel C, Oswald D, Larrosa-Lombardi S, Barchfeld T, Cleff U. Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19. J Neurol. 2021, 268:3125-8. 10.1007\/s00415-021-10428-6","journal-title":"J Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/296836-successful-control-of-myasthenic-crisis-after-the-introduction-of-ravulizumab-in-myasthenia-gravis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T05:07:04Z","timestamp":1732165624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/296836-successful-control-of-myasthenic-crisis-after-the-introduction-of-ravulizumab-in-myasthenia-gravis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.74117","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,20]]}}}